We are live on ! Find out more
VCYT icon

Veracyte

55 hedge funds and large institutions have $119M invested in Veracyte in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 23 increasing their positions, 11 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

109% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 11

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

53% more capital invested

Capital invested by funds: $77.5M → $119M (+$41.3M)

5% less funds holding

Funds holding: 5855 (-3)

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $529K

Holders
55
Holders Change
-3
Holders Change %
-5.17%
% of All Funds
1.46%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
4
Increased
23
Reduced
11
Closed
7
Calls
Puts
$529K
Net Calls
-$529K
Net Calls Change
+$714K

VCYT Hedge Fund Activity: Q3 2016 in Review

55 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Veracyte (VCYT) for Q3 2016, worth a combined $119M — up 53% from $77.5M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of VCYT and 4 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 23 added.

The largest buyer was Cannell Capital, opening a new position worth an estimated $2.15M. The largest seller was Clough Capital Partners, exiting entirely with an estimated $1.35M sold.

  • 55 institutional investors held Veracyte (VCYT) as of Q3 2016, down from 58 in Q2 2016.
  • Funds reported $119M of Veracyte stock for Q3 2016, up 53% quarter-over-quarter.
  • 4 funds opened new Veracyte positions in Q3 2016 and 7 closed out, a net change of -3 holders.
  • The largest Veracyte buyer in Q3 2016 was Cannell Capital, an estimated $2.15M added.
  • The largest Veracyte seller in Q3 2016 was Clough Capital Partners, an estimated $1.35M sold.

Based on aggregated 13F filings for Q3 2016.